Mold Tek Packaging

Mold-Tek delivered a strong Q4 FY26 with 13.4%Current reported value: 13.4%. No comparable prior figure is available in the source record. revenue growth and EBITDA margin expansion of 310 bpsCurrent reported value: 310 bps. No comparable prior figure is available in the source record. to 40.7%Current reported value: 40.7%. No comparable prior figure is available in the source record., driven by consolidation of Hyderabad units, higher capacity utilization (now ~65%Current 65%. Reported change: +15pp YoY.), and a 219%Current reported value: 219%. No comparable prior figure is available in the source record. surge in pharma sales to ₹34.3 CrCurrent ₹34.3 Cr. Reported change: +219% YoY.. Paint segment grew 14.4% with Asian Paints recovering (+17% in Q4) and ABG up 60%Current 60%. Reported change: +60% YoY.. Lubricants declined due to BPCL loss but stabilized. Management guides for 13-15%Current reported value: 13-15%. No comparable prior figure is available in the source record. value growth in FY27, pharma target of ₹50-55 Cr, and EBITDA margin of 42.5-43%Current reported value: 42.5-43%. No comparable prior figure is available in the source record.. Capex to moderate to ₹80-85 Cr. Key risk: further escalation of West Asia war disrupting raw material supply or demand.